NCT00840099View on ClinicalTrials.gov

600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

August 31, 2002

Study Completion Date

August 31, 2002

Conditions
Healthy
Interventions
DRUG

600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL

1 x 600 mg/42.9 mg/5 mL, single-dose fed

DRUG

Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension

1 x 600 mg/42.9 mg/5 mL, single-dose fed

Trial Locations (1)

M1R 5A3

Pharma Medica Research Inc., Toronto

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00840099 - 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions | Biotech Hunter | Biotech Hunter